Edition:
India

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

3.75USD
2:29am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.75
Open
$3.65
Day's High
$3.85
Day's Low
$3.60
Volume
3,692
Avg. Vol
5,867
52-wk High
$5.35
52-wk Low
$2.45

Chart for

About

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $55.33
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

BRIEF-KemPharm posts Q3 loss per share $0.68

* KemPharm reports third quarter 2017 results and provides corporate update

10 Nov 2017

BRIEF-KemPharm receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511

* KemPharm Inc receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511 Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-KemPharm says KP484 allowed to proceed to clinical studies​

* kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies

02 Nov 2017

BRIEF-KemPharm files IND application for KP484 for the treatment of ADHD

* KemPharm files IND for KP484 for the treatment of ADHD, an investigational prodrug of methylphenidate

20 Sep 2017

BRIEF-Kempharm announces preliminary results from KP415 pharmacokinetic single and multiple dose trial

* Kempharm announces preliminary results from KP415 pharmacokinetic single and multiple dose trial

10 Aug 2017

BRIEF-KemPharm strengthens ADHD prodrug pipeline with development of KP484

* KemPharm strengthens adhd prodrug pipeline with development of KP484, a new, super-extended release adhd methylphenidate product candidate

28 Jun 2017

Earnings vs. Estimates